Sentara Heart Valve and Structural Disease Center, Sentara Heart Hospital, 600 Gresham Drive, Norfolk, VA 23507 USA.
J Invasive Cardiol. 2020 Jul;32(7):E182-E185. doi: 10.25270/jic/20.00133.
Patient prosthesis mismatch (PPM) is an iatrogenic complication that occurs in patients who undergo surgical aortic valve replacement (SAVR). PPM occurs when the implanted surgical valve has an effective orifice area (EOA) that is too small for the patient, resulting in a gradient across the valve despite an otherwise normally functioning prosthesis. PPM has been associated with mid- and long-term increased morbidity and mortality. When this occurs, repeat SAVR with root enlargement and implantation of a larger prosthesis is traditionally employed; however, this approach involves the risks of morbidity and mortality of redo surgery, which may be prohibitive in critically ill or medically complex patients. Bioprosthetic valve fracture (BVF), where high-pressure balloon inflation is employed to fracture the surgical valve sewing ring to increase the EOA, has been used as an adjunct for valve-in-valve (transcatheter aortic valve in surgical aortic valve [TAV in SAV]) procedures for degenerated surgical valves to increase EOA, but has not yet been reported as standalone therapy for early PPM after SAVR.
We present a case of a 41-year-old male (body surface area, 2.3 m²) who presented 4 months after SAVR with a 21 mm surgical valve (Magna Ease, true inner diameter, 19 mm) with severe PPM (mean gradient, 43 mm Hg) despite normal functioning valvular prosthetic leaflets, associated with debilitating symptoms. This patient was deemed high risk by the heart team, and was successfully treated with TAV in SAV (26 mm Evolut R) and concomitant high-pressure bioprosthetic valve fracture (BVF) with a 22 mm high-pressure balloon. The patient tolerated the procedure well; mean gradient was 5 mm Hg post BVF and prompt resolution of symptoms was seen. His postprocedure recovery was uneventful and his symptoms resolved, allowing him to return to work within a week of his hospital discharge. BVF associated with TAV in SAV appears to be a feasible approach for treatment of severe symptomatic PPM even in the early postoperative period with otherwise normally functioning prosthesis.
人工瓣膜-患者不匹配(PPM)是一种医源性并发症,发生于接受主动脉瓣置换术(SAVR)的患者中。当植入的外科瓣膜的有效开口面积(EOA)对于患者来说太小,导致即使瓣膜功能正常,但仍有跨瓣梯度时,就会发生 PPM。PPM 与中、长期发病率和死亡率增加有关。当这种情况发生时,传统上采用重复 SAVR 并扩大根部和植入更大的瓣膜来治疗;然而,这种方法涉及 redo 手术的发病率和死亡率风险,对于重症或患有复杂疾病的患者来说可能是禁忌的。生物瓣破裂(BVF),即使用高压球囊充气来破裂外科瓣膜的缝合环以增加 EOA,已被用作经导管主动脉瓣置换术(TAV)治疗退行性外科瓣膜的瓣中瓣(外科主动脉瓣中的经导管主动脉瓣 [TAV 在 SAV])手术的辅助手段,以增加 EOA,但尚未报道作为 SAVR 后早期 PPM 的单独治疗方法。
我们介绍了一例 41 岁男性(体表面积,2.3m²),在 SAV 后 4 个月出现 21mm 外科瓣膜(Magna Ease,真内径 19mm)严重 PPM(平均梯度 43mmHg),尽管瓣叶功能正常,但仍有严重症状。该患者被心脏团队认为是高危患者,成功接受了 TAV 在 SAV(26mm Evolut R)和同时进行的高压生物瓣破裂(BVF)治疗,使用了 22mm 高压球囊。患者对该程序耐受良好;BVF 后平均梯度为 5mmHg,症状迅速缓解。他的术后恢复顺利,症状缓解,在出院后一周内恢复工作。TAV 在 SAV 中联合 BVF 似乎是一种可行的方法,即使在术后早期,对于有症状的严重 PPM 也能有效治疗,而瓣叶功能正常。